Larimar Therapeutics, Inc. (LRMR)
Automate Your Wheel Strategy on LRMR
With Tiblio's Option Bot, you can configure your own wheel strategy including LRMR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LRMR
- Rev/Share 0.0038
- Book/Share 2.2555
- PB 1.5429
- Debt/Equity 0.0337
- CurrentRatio 7.4765
- ROIC -0.7116
- MktCap 222817092.0
- FreeCF/Share -1.3672
- PFCF -2.5478
- PE -2.3374
- Debt/Assets 0.0286
- DivYield 0
- ROE -0.5248
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LRMR | Truist | -- | Buy | -- | $18 | Jan. 29, 2025 |
| Initiation | LRMR | Oppenheimer | -- | Outperform | -- | $26 | Oct. 16, 2024 |
| Initiation | LRMR | Wedbush | -- | Outperform | -- | $22 | Oct. 3, 2024 |
| Initiation | LRMR | H.C. Wainwright | -- | Buy | -- | $15 | Oct. 2, 2024 |
News
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA Written FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated approval planned in the second quarter of 2026 to allow for inclusion of the recommended safety data for adults and children OLE data expected in September 2025 from 30-40 participants who received at least one …
Read More
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company's nomlabofusp clinical development program for the treatment of Friedreich's Ataxia on Monday, June 23, 2025 at 8:00 am EDT.
Read More
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BALA CYNWYD, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2024 operating and financial results.
Read More
About Larimar Therapeutics, Inc. (LRMR)
- IPO Date 2014-06-19
- Website https://www.larimartx.com
- Industry Biotechnology
- CEO Carole S. Ben-Maimon
- Employees 65